Literature DB >> 25387664

Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts.

Patricia Font1, Javier Loscertales, Carlos Soto, Pilar Ricard, Carolina Muñoz- Novas, Estela Martín-Clavero, Montserrat López-Rubio, Luis Garcia-Alonso, Marta Callejas, Alfredo Bermejo, Celina Benavente, Mónica Ballesteros, Teresa Cedena, María Calbacho, Raquel Urbina, Jesús Villarrubia, Santiago Gil, José María Bellón, José Luis Diez-Martin, Ana Villegas.   

Abstract

Previous studies have shown the reproducibility of the 2008 World Health Organization (WHO) classification in myelodysplastic syndromes (MDS), especially when multilineage dysplasia or excess of blasts are present. However, there are few data regarding the reproducibility of MDS with unilineage dysplasia. The revised International Prognostic Scoring System R-IPSS described two new morphological categories, distinguishing bone marrow (BM) blast cell count between 0-2 % and >2- < 5 %. This distinction is critical for establishing prognosis, but the reproducibility of this threshold is still not demonstrated. The objectives of our study were to explore the reliability of the 2008 WHO classification, regarding unilineage vs. multilineage dysplasia, by reviewing 110 cases previously diagnosed with MDS, and to study whether the threshold of ≤2 % BM blasts is reproducible among different observers. We used the same methodology as in our previous paper [Font et al. (2013) Ann Hematol 92:19-24], by encouraging investigators to include patients with <5 % BM blasts. Samples were collected from 11 hospitals and were evaluated by 11 morphologists. Each observer evaluated 20 samples, and each sample was analyzed independently by two morphologists. Discordance was observed in 36/108 suitable cases (33 %, kappa test 0.503). Diagnosis of MDS with unilineage dysplasia (refractory cytopenia with unilineage dysplasia (RCUD), refractory anemia with ring sideroblasts (RARS) or unclassifiable MDS) was assessed in 33 patients, by either of the two observers. We combined this series with the cases with RCUD or RARS included in our 2013 paper, thus obtaining 50 cases with unilineage dysplasia by at least one of the observers. The whole series showed very low agreement regarding RCUD (5/23, 21 %) and RARS (5/28, 18 %). Regarding BM blast count, the threshold of ≤2 % was not reproducible (discordance rate 32/108 cases, kappa test 0.277). Our study shows that among MDS WHO 2008 categories, interobserver discordance seems to be high in cases with unilineage dysplasia. We also illustrate that the threshold of ≤2 % BM blasts as settled by the R-IPSS may be not easy to reproduce by morphologists in real practice.

Entities:  

Mesh:

Year:  2014        PMID: 25387664     DOI: 10.1007/s00277-014-2252-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  13 in total

1.  Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.

Authors:  Eric J Duncavage; Geoffrey L Uy; Allegra A Petti; Christopher A Miller; Yi-Shan Lee; Bevan Tandon; Feng Gao; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Meagan A Jacoby; Amanda F Cashen; Lukas D Wartman; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley; John S Welch
Journal:  Blood       Date:  2017-01-12       Impact factor: 22.113

Review 2.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Authors:  Aaron C Shaver; Adam C Seegmiller
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

3.  MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.

Authors:  Brian Kwok; Jeff M Hall; John S Witte; Yin Xu; Prashanti Reddy; Keming Lin; Rachel Flamholz; Bashar Dabbas; Aine Yung; Jenan Al-Hafidh; Emily Balmert; Christine Vaupel; Carlos El Hader; Matthew J McGinniss; Shareef A Nahas; Julie Kines; Rafael Bejar
Journal:  Blood       Date:  2015-10-01       Impact factor: 22.113

4.  The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.

Authors:  Christopher R Cogle; Sandra E Kurtin; Tanya G K Bentley; Michael S Broder; Eunice Chang; Scott Megaffin; Steven Fruchtman; Michael E Petrone; Sudipto Mukherjee
Journal:  Oncologist       Date:  2017-03-10

Review 5.  "Blasts" in myeloid neoplasms - how do we define blasts and how do we incorporate them into diagnostic schema moving forward?

Authors:  Xueyan Chen; Jonathan R Fromm; Kikkeri N Naresh
Journal:  Leukemia       Date:  2022-01-19       Impact factor: 11.528

Review 6.  Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?

Authors:  Rafael Bejar
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

Review 7.  Refractory thrombocytopenia and neutropenia: a diagnostic challenge.

Authors:  Emmanuel Gyan; François Dreyfus; Pierre Fenaux
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-02-18       Impact factor: 2.576

8.  Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance.

Authors:  Louise de Swart; Alex Smith; Marius MacKenzie; Argiris Symeonidis; Judith Neukirchen; Dana Mikulenková; Teresa Vallespí; Gina Zini; Malgorzata Paszkowska-Kowalewska; Anton Kruger; Leonie Saft; Pierre Fenaux; David Bowen; Eva Hellström-Lindberg; Jaroslav Čermák; Reinhard Stauder; Aurelia Tatic; Mette Skov Holm; Luca Malcovati; Krzysztof Mądry; Jackie Droste; Nicole Blijlevens; Theo de Witte; Ulrich Germing
Journal:  Ann Hematol       Date:  2017-05-20       Impact factor: 3.673

9.  Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients.

Authors:  Jonathan Chiou; Allison Chiou; Rong He; Dong Chen; Constance P Chen; Caroline Spethman; Kurt R Bessonen; Jennifer L Oliveira; Phuong L Nguyen; Kaaren K Reichard; James D Hoyer; Simon D Althoff; Dana J Roh; Mechelle A Miller; Ji Yuan; Horatiu Olteanu; Kebede Begna; Ayalew Tefferi; Hassan Alkhateeb; Mrinal M Patnaik; Mark R Litzow; Aref Al-Kali; David S Viswanatha
Journal:  Blood Cancer J       Date:  2022-01-25       Impact factor: 11.037

10.  Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.

Authors:  John F Seymour; Hartmut Döhner; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal Del Castillo; Haifa Kathrin Al-Ali; Jose Falantes; Richard M Stone; Mark D Minden; Jerry Weaver; Steve Songer; C L Beach; Hervé Dombret
Journal:  BMC Cancer       Date:  2017-12-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.